Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 377

1.

177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy.

Banerjee SR, Kumar V, Lisok A, Chen J, Minn I, Brummet M, Boinapally S, Cole M, Ngen E, Wharram B, Brayton C, Hobbs RF, Pomper MG.

Eur J Nucl Med Mol Imaging. 2019 Aug 10. doi: 10.1007/s00259-019-04434-0. [Epub ahead of print]

PMID:
31399803
2.

Characterizing the Link Between Glial Activation and Changed Functional Connectivity in National Football League Players Using Multimodal Neuroimaging.

Peters ME, Rahman S, Coughlin JM, Pomper MG, Sair HI.

J Neuropsychiatry Clin Neurosci. 2019 Aug 9:appineuropsych18110274. doi: 10.1176/appi.neuropsych.18110274. [Epub ahead of print]

PMID:
31394988
3.

Can the interplay between androgen signaling and PSMA expression be leveraged for theranostic applications?

Batra JS, Pienta KJ, Pomper MG, Gorin MA, Rowe SP.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S263-S264. doi: 10.21037/tau.2019.03.13. No abstract available.

4.

Imager-4D: New Software for Viewing Dynamic PET Scans and Extracting Radiomic Parameters from PET Data.

Rowe SP, Solnes LB, Yin Y, Kitchen G, Lodge MA, Karakatsanis NA, Rahmim A, Pomper MG, Leal JP.

J Digit Imaging. 2019 Aug 6. doi: 10.1007/s10278-019-00255-7. [Epub ahead of print]

PMID:
31388864
5.

Enhancing CAR T-cell therapy through cellular imaging and radiotherapy.

Minn I, Rowe SP, Pomper MG.

Lancet Oncol. 2019 Aug;20(8):e443-e451. doi: 10.1016/S1470-2045(19)30461-9. Epub 2019 Jul 29. Review.

PMID:
31364596
6.

A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.

Paller CJ, Piana D, Eshleman JR, Riel S, Denmeade SR, Isaacsson Velho P, Rowe SP, Pomper MG, Antonarakis ES, Luo J, Eisenberger MA.

Prostate. 2019 Jul 30. doi: 10.1002/pros.23883. [Epub ahead of print]

PMID:
31361358
7.

Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT.

Werner RA, Thackeray JT, Pomper MG, Bengel FM, Gorin MA, Derlin T, Rowe SP.

J Clin Med. 2019 Jul 19;8(7). pii: E1060. doi: 10.3390/jcm8071060. Review.

8.

Imaging CAR T cell therapy with PSMA-targeted positron emission tomography.

Minn I, Huss DJ, Ahn HH, Chinn TM, Park A, Jones J, Brummet M, Rowe SP, Sysa-Shah P, Du Y, Levitsky HI, Pomper MG.

Sci Adv. 2019 Jul 3;5(7):eaaw5096. doi: 10.1126/sciadv.aaw5096. eCollection 2019 Jul.

9.

Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease.

Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, Lee JH, Kim WR, Kook M, Foss CA, Shen C, Lee H, Kulkarni S, Pasricha PJ, Lee G, Pomper MG, Dawson VL, Dawson TM, Ko HS.

Neuron. 2019 Jun 26. pii: S0896-6273(19)30488-X. doi: 10.1016/j.neuron.2019.05.035. [Epub ahead of print]

PMID:
31255487
10.

Preclinical evaluation of 203/212Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer.

Ray Banerjee S, Minn IL, Kumar V, Josefsson A, Lisok A, Brummet M, Chen J, Kiess A, Baidoo K, Brayton C, Mease RC, Brechbiel M, Sgouros G, Hobbs RF, Pomper MG.

J Nucl Med. 2019 Jun 28. pii: jnumed.119.229393. doi: 10.2967/jnumed.119.229393. [Epub ahead of print]

PMID:
31253744
11.

[68Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas.

Breun M, Monoranu CM, Kessler AF, Matthies C, Löhr M, Hagemann C, Schirbel A, Rowe SP, Pomper MG, Buck AK, Wester HJ, Ernestus RI, Lapa C.

Front Oncol. 2019 Jun 12;9:503. doi: 10.3389/fonc.2019.00503. eCollection 2019.

12.

Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls.

Sheikhbahaei S, Werner RA, Solnes LB, Pienta KJ, Pomper MG, Gorin MA, Rowe SP.

Semin Nucl Med. 2019 Jul;49(4):255-270. doi: 10.1053/j.semnuclmed.2019.02.006. Epub 2019 Mar 4. Review.

PMID:
31227049
13.

Prospective Evaluation of PSMA-Targeted 18F-DCFPyL PET/CT in Men with Biochemical Failure after Radical Prostatectomy for Prostate Cancer.

Rowe SP, Campbell SP, Mana-Ay M, Szabo Z, Allaf ME, Pienta KJ, Pomper MG, Ross AE, Gorin MA.

J Nucl Med. 2019 Jun 14. pii: jnumed.119.226514. doi: 10.2967/jnumed.119.226514. [Epub ahead of print]

PMID:
31201249
14.

Development of [18F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide.

Lesniak WG, Mease RC, Chatterjee S, Kumar D, Lisok A, Wharram B, Kalagadda VR, Emens LA, Pomper MG, Nimmagadda S.

Mol Imaging. 2019 Jan-Dec;18:1536012119852189. doi: 10.1177/1536012119852189.

15.

PET imaging of distinct brain uptake of a nanobody and similarly-sized PAMAM dendrimers after intra-arterial administration.

Lesniak WG, Chu C, Jablonska A, Behnam Azad B, Zwaenepoel O, Zawadzki M, Lisok A, Pomper MG, Walczak P, Gettemans J, Janowski M.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1940-1951. doi: 10.1007/s00259-019-04347-y. Epub 2019 Jun 3.

PMID:
31161257
16.

Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT.

Meyer AR, Carducci MA, Denmeade SR, Markowski MC, Pomper MG, Pierorazio PM, Allaf ME, Rowe SP, Gorin MA.

Ann Nucl Med. 2019 Aug;33(8):617-623. doi: 10.1007/s12149-019-01371-8. Epub 2019 May 30.

PMID:
31147927
17.

The next era of renal radionuclide imaging: novel PET radiotracers.

Werner RA, Chen X, Lapa C, Koshino K, Rowe SP, Pomper MG, Javadi MS, Higuchi T.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1773-1786. doi: 10.1007/s00259-019-04359-8. Epub 2019 May 30.

18.

Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake.

Werner RA, Bundschuh RA, Bundschuh L, Lapa C, Yin Y, Javadi MS, Buck AK, Higuchi T, Pienta KJ, Pomper MG, Lodge MA, Gorin MA, Rowe SP.

Mol Imaging Biol. 2019 May 28. doi: 10.1007/s11307-019-01375-w. [Epub ahead of print]

PMID:
31140110
19.

From the Reading Room to the Courtroom-The Use of Molecular Radionuclide Imaging in Criminal Trials.

Werner RA, Savoie B, Javadi MS, Pomper MG, Higuchi T, Lapa C, Rowe SP.

J Am Coll Radiol. 2019 May 24. pii: S1546-1440(19)30567-8. doi: 10.1016/j.jacr.2019.05.001. [Epub ahead of print]

PMID:
31132333
20.

Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ Uptake.

Sahakyan K, Li X, Lodge MA, Werner RA, Bundschuh RA, Bundschuh L, Kulkarni HR, Schuchardt C, Baum RP, Pienta KJ, Pomper MG, Ross AE, Gorin MA, Rowe SP.

Mol Imaging Biol. 2019 May 21. doi: 10.1007/s11307-019-01376-9. [Epub ahead of print]

PMID:
31115751
21.

Evaluation of PSMA-Targeted PAMAM Dendrimer Nanoparticles in a Murine Model of Prostate Cancer.

Lesniak WG, Boinapally S, Banerjee SR, Behnam Azad B, Foss CA, Shen C, Lisok A, Wharram B, Nimmagadda S, Pomper MG.

Mol Pharm. 2019 Jun 3;16(6):2590-2604. doi: 10.1021/acs.molpharmaceut.9b00181. Epub 2019 May 6.

PMID:
31002252
22.

The effect of ApoE ε4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study.

Paranjpe MD, Chen X, Liu M, Paranjpe I, Leal JP, Wang R, Pomper MG, Wong DF, Benzinger TLS, Zhou Y; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2019;22:101795. doi: 10.1016/j.nicl.2019.101795. Epub 2019 Mar 28.

23.

MRI Assessment of Prostate-Specific Membrane Antigen (PSMA) Targeting by a PSMA-Targeted Magnetic Nanoparticle: Potential for Image-Guided Therapy.

Ngen EJ, Benham Azad B, Boinapally S, Lisok A, Brummet M, Jacob D, Pomper MG, Banerjee SR.

Mol Pharm. 2019 May 6;16(5):2060-2068. doi: 10.1021/acs.molpharmaceut.9b00036. Epub 2019 Apr 10.

PMID:
30912947
24.

Opportunities in precision psychiatry using PET neuroimaging in psychosis.

Coughlin JM, Horti AG, Pomper MG.

Neurobiol Dis. 2019 Mar 20. pii: S0969-9961(19)30070-1. doi: 10.1016/j.nbd.2019.03.016. [Epub ahead of print] Review.

PMID:
30904669
25.

Association of PET-measured myocardial flow reserve with echocardiography-estimated pulmonary artery systolic pressure in patients with hypertrophic cardiomyopathy.

Zhao M, Liu M, Leal JP, Tsui BMW, Wong DF, Pomper MG, Zhou Y.

PLoS One. 2019 Mar 20;14(3):e0212573. doi: 10.1371/journal.pone.0212573. eCollection 2019.

26.

Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma.

Park JS, Oh Y, Park YJ, Park O, Yang H, Slania S, Hummers LK, Shah AA, An HT, Jang J, Horton MR, Shin J, Dietz HC, Song E, Na DH, Park EJ, Kim K, Lee KC, Roschke VV, Hanes J, Pomper MG, Lee S.

Nat Commun. 2019 Mar 8;10(1):1128. doi: 10.1038/s41467-019-09101-4.

27.

Imaging and Characterization of Macrophage Distribution in Mouse Models of Human Prostate Cancer.

Copeland BT, Shallal H, Shen C, Pienta KJ, Foss CA, Pomper MG.

Mol Imaging Biol. 2019 Feb 25. doi: 10.1007/s11307-019-01318-5. [Epub ahead of print]

PMID:
30805886
28.

The Correlation Between [68Ga]DOTATATE PET/CT and Cell Proliferation in Patients With GEP-NENs.

Yu J, Li N, Li J, Lu M, Leal JP, Tan H, Su H, Fan Y, Zhang Y, Zhao W, Zhu H, Pomper MG, Zhou Y, Yang Z.

Mol Imaging Biol. 2019 Feb 22. doi: 10.1007/s11307-019-01328-3. [Epub ahead of print]

PMID:
30796708
29.

Novel Structured Reporting Systems for Theranostic Radiotracers.

Werner RA, Bundschuh RA, Bundschuh L, Fanti S, Javadi MS, Higuchi T, Weich A, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Herrmann K, Lapa C, Rowe SP.

J Nucl Med. 2019 May;60(5):577-584. doi: 10.2967/jnumed.118.223537. Epub 2019 Feb 22.

PMID:
30796171
30.

Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT.

Gomez E, Tran PT, Pienta KJ, Pomper MG, Gorin MA, Rowe SP.

Clin Nucl Med. 2019 Apr;44(4):e313-e314. doi: 10.1097/RLU.0000000000002489.

PMID:
30789396
31.

Novel Functional Renal PET Imaging With 18F-FDS in Human Subjects.

Werner RA, Ordonez AA, Sanchez-Bautista J, Marcus C, Lapa C, Rowe SP, Pomper MG, Leal JP, Lodge MA, Javadi MS, Jain SK, Higuchi T.

Clin Nucl Med. 2019 May;44(5):410-411. doi: 10.1097/RLU.0000000000002494.

PMID:
30762825
32.

PSMA-targeted [18F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework.

Reyes DK, Demehri S, Werner RA, Pomper MG, Gorin MA, Rowe SP, Pienta KJ.

Urol Case Rep. 2019 Jan 9;23:72-74. doi: 10.1016/j.eucr.2019.01.007. eCollection 2019 Mar.

33.

A comparison of prostate cancer bone metastases on 18F-Sodium Fluoride and Prostate Specific Membrane Antigen (18F-PSMA) PET/CT: Discordant uptake in the same lesion.

Harmon SA, Mena E, Shih JH, Adler S, McKinney Y, Bergvall E, Mehralivand S, Sowalsky AG, Couvillon A, Madan RA, Gulley JL, Eary J, Mease RC, Pomper MG, Dahut WL, Turkbey B, Lindenberg L, Choyke PL.

Oncotarget. 2018 Dec 28;9(102):37676-37688. doi: 10.18632/oncotarget.26481. eCollection 2018 Dec 28.

34.

Imaging of Prostate-Specific Membrane Antigen with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical Applications.

Rowe SP, Gorin MA, Pomper MG.

Annu Rev Med. 2019 Jan 27;70:461-477. doi: 10.1146/annurev-med-062117-073027.

PMID:
30691373
35.

PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R).

Horti AG, Naik R, Foss CA, Minn I, Misheneva V, Du Y, Wang Y, Mathews WB, Wu Y, Hall A, LaCourse C, Ahn HH, Nam H, Lesniak WG, Valentine H, Pletnikova O, Troncoso JC, Smith MD, Calabresi PA, Savonenko AV, Dannals RF, Pletnikov MV, Pomper MG.

Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1686-1691. doi: 10.1073/pnas.1812155116. Epub 2019 Jan 11.

36.

The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?

Werner RA, Weich A, Kircher M, Solnes LB, Javadi MS, Higuchi T, Buck AK, Pomper MG, Rowe SP, Lapa C.

Theranostics. 2018 Nov 29;8(22):6088-6100. doi: 10.7150/thno.30357. eCollection 2018. Review.

37.

Generative Adversarial Networks for the Creation of Realistic Artificial Brain Magnetic Resonance Images.

Kazuhiro K, Werner RA, Toriumi F, Javadi MS, Pomper MG, Solnes LB, Verde F, Higuchi T, Rowe SP.

Tomography. 2018 Dec;4(4):159-163. doi: 10.18383/j.tom.2018.00042.

38.

The availability of the α7 nicotinic acetylcholine receptor in recent-onset psychosis: a study using 18F-ASEM PET.

Coughlin J, Du Y, Crawford JL, Rubin LH, Behnam Azad B, Lesniak WG, Horti AG, Schretlen DJ, Sawa A, Pomper MG.

J Nucl Med. 2018 Dec 20. pii: jnumed.118.213686. doi: 10.2967/jnumed.118.213686. [Epub ahead of print]

PMID:
30573639
39.

Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [11C]DPA-713 PET.

Coughlin JM, Yang T, Rebman AW, Bechtold KT, Du Y, Mathews WB, Lesniak WG, Mihm EA, Frey SM, Marshall ES, Rosenthal HB, Reekie TA, Kassiou M, Dannals RF, Soloski MJ, Aucott JN, Pomper MG.

J Neuroinflammation. 2018 Dec 19;15(1):346. doi: 10.1186/s12974-018-1381-4.

40.

Peptide-based PET quantifies target engagement of PD-L1 therapeutics.

Kumar D, Lisok A, Dahmane E, McCoy M, Shelake S, Chatterjee S, Allaj V, Sysa-Shah P, Wharram B, Lesniak WG, Tully E, Gabrielson E, Jaffee EM, Poirier JT, Rudin CM, Gobburu JV, Pomper MG, Nimmagadda S.

J Clin Invest. 2019 Feb 1;129(2):616-630. doi: 10.1172/JCI122216. Epub 2019 Jan 7.

41.

Impact of Tumor Burden on Quantitative [68Ga] DOTATOC Biodistribution.

Werner RA, Hänscheid H, Leal JP, Javadi MS, Higuchi T, Lodge MA, Buck AK, Pomper MG, Lapa C, Rowe SP.

Mol Imaging Biol. 2019 Aug;21(4):790-798. doi: 10.1007/s11307-018-1293-9.

PMID:
30406512
42.

Identifying Recurrent Malignant Glioma after Treatment Using Amide Proton Transfer-Weighted MR Imaging: A Validation Study with Image-Guided Stereotactic Biopsy.

Jiang S, Eberhart CG, Lim M, Heo HY, Zhang Y, Blair L, Wen Z, Holdhoff M, Lin D, Huang P, Qin H, Quinones-Hinojosa A, Weingart JD, Barker PB, Pomper MG, Laterra J, van Zijl PCM, Blakeley JO, Zhou J.

Clin Cancer Res. 2019 Jan 15;25(2):552-561. doi: 10.1158/1078-0432.CCR-18-1233. Epub 2018 Oct 26.

PMID:
30366937
43.

Tuning Pharmacokinetics to Improve Tumor Accumulation of a Prostate-Specific Membrane Antigen-Targeted Phototheranostic Agent.

Harmatys KM, Overchuk M, Chen J, Ding L, Chen Y, Pomper MG, Zheng G.

Bioconjug Chem. 2018 Nov 21;29(11):3746-3756. doi: 10.1021/acs.bioconjchem.8b00636. Epub 2018 Oct 29.

PMID:
30350576
44.

A Distinct Advantage to Intraarterial Delivery of 89Zr-Bevacizumab in PET Imaging of Mice With and Without Osmotic Opening of the Blood-Brain Barrier.

Lesniak WG, Chu C, Jablonska A, Du Y, Pomper MG, Walczak P, Janowski M.

J Nucl Med. 2019 May;60(5):617-622. doi: 10.2967/jnumed.118.218792. Epub 2018 Oct 12.

PMID:
30315146
45.

Uptake of Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL in Cerebral Radionecrosis: Implications for Diagnostic Imaging of High-Grade Gliomas.

Salas Fragomeni RA, Pienta KJ, Pomper MG, Gorin MA, Rowe SP.

Clin Nucl Med. 2018 Nov;43(11):e419-e421. doi: 10.1097/RLU.0000000000002280.

PMID:
30247210
46.

Evaluation of 111In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen.

Banerjee SR, Kumar V, Lisok A, Plyku D, Nováková Z, Brummet M, Wharram B, Barinka C, Hobbs R, Pomper MG.

J Nucl Med. 2019 Mar;60(3):400-406. doi: 10.2967/jnumed.118.214403. Epub 2018 Sep 20.

PMID:
30237212
47.

Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT.

Yin Y, Campbell SP, Markowski MC, Pierorazio PM, Pomper MG, Allaf ME, Rowe SP, Gorin MA.

Mol Imaging Biol. 2019 Jun;21(3):567-573. doi: 10.1007/s11307-018-1271-2.

PMID:
30218388
48.

Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging.

Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Leal JP, Higuchi T, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Lapa C, Rowe SP.

J Nucl Med. 2018 Dec;59(12):1857-1864. doi: 10.2967/jnumed.118.217588. Epub 2018 Sep 6.

49.

Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.

Yin Y, Werner RA, Higuchi T, Lapa C, Pienta KJ, Pomper MG, Gorin MA, Rowe SP.

J Nucl Med. 2019 Apr;60(4):511-516. doi: 10.2967/jnumed.118.217653. Epub 2018 Sep 6.

PMID:
30190303
50.

Nanoparticle architecture preserves magnetic properties during coating to enable robust multi-modal functionality.

Woodard LE, Dennis CL, Borchers JA, Attaluri A, Velarde E, Dawidczyk C, Searson PC, Pomper MG, Ivkov R.

Sci Rep. 2018 Aug 23;8(1):12706. doi: 10.1038/s41598-018-29711-0.

Supplemental Content

Loading ...
Support Center